Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P17342
UPID:
ANPRC_HUMAN
Alternative names:
Atrial natriuretic peptide clearance receptor; Atrial natriuretic peptide receptor type C
Alternative UPACC:
P17342; A2RRD1; B4DT84; E7EPG9
Background:
Atrial natriuretic peptide receptor 3 (ANPR-C) serves as a key receptor for natriuretic peptide hormones, including ANP, BNP, and CNP. It plays a crucial role in regulating diuresis, blood pressure, and skeletal development by acting as a clearance receptor, thus controlling the local concentrations and effects of these peptides without possessing guanylate cyclase activity.
Therapeutic significance:
Linked to Boudin-Mortier syndrome, a disorder characterized by tall stature, long digits, and cardiovascular anomalies, ANPR-C's involvement suggests potential therapeutic targets. Understanding its role could pave the way for innovative treatments for this autosomal recessive disorder.